Pharma 4.0 is no longer a future ambition; it’s the baseline. The ability to operate with real-time data, integrated systems, ...

As excitement builds around GLP-1s and their expanding list of potential indications, the conversation is shifting from hype ...

Grant funding calls are often over-subscribed and success rates can be low. Excellent applications sometimes fail to be ...

The UK has started a 'world-first' gonorrhoea vaccination programme that is designed to prevent thousands of cases and save ...

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and ...

Vertex already has FDA approval for NaV1.8 inhibitor Journavx (suzetrigine) in acute pain, with late-stage trials on the go ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

The importance of China as a growth market for pharma multinationals is underlined by the news that Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug under review for ...

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

The disruption at the FDA continues with the departure of CBER director Vinay Prasad, less than three months after taking on the role.

The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on imports into the US – does extend to most pharmaceutical products ...